Bonnie Bassler - Regeneron Pharmaceuticals Director

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

Dr. Bonnie Bassler, Ph.D., is an Independent Director of the Company. Dr. Bassler is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served as the President of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation, and the American Academy of Microbiology. She was elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society of London, and the American Philosophical Society, and has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award, and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her B.Sc. from the University of California, Davis, and her Ph.D. in Biochemistry from Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, CA, before becoming a faculty member at Princeton University
Age: 55  Director Since 2016      
914 847 7000
Bassler served as a director of Sanofi from November 2014 to July 2016.

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3 M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Geoffrey ParkerPerrigo Company Plc
Linda RhodesZoetis
Bruce CarterDr Reddys Laboratories Ltd
Fei WangOrigin Agritech Limited
Gregory NordenZoetis
Paul BisaroZoetis
Jacqualyn FousePerrigo Company Plc
William SteereZoetis
Sanjay KhoslaZoetis
David AltshulerVertex Pharmaceuticals Incorpor
Theodore SamuelsPerrigo Company Plc
Prasad MenonDr Reddys Laboratories Ltd
Omkar GoswamiDr Reddys Laboratories Ltd
David GreenwayVertex Pharmaceuticals Incorpor
Rolf ClassonPerrigo Company Plc
Allan ObermanDr Reddys Laboratories Ltd
Terrence KearneyVertex Pharmaceuticals Incorpor
Theodore SamuelstoPerrigo Company Plc
Laurie BrlasPerrigo Company Plc
Kalpana MorpariaDr Reddys Laboratories Ltd
David BullockOrigin Agritech Limited

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run ETF Directory Now


ETF Directory

Find actively-traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased few shares of
few hours ago
Traded for 177.06
Purchased over 300 shares of
few hours ago
Traded for 8.78
Purchased over 70 shares of
few hours ago
Traded for 35.57
Purchased over 400 shares of
few hours ago
Traded for 6.42
Purchased a lot of shares of
few hours ago
Traded for 154.95
Additionally take a look at Your Equity Center. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.